empoweringmuscleempoweringlives
As a leader in muscle biology research, we are dedicated to our mission of improving the lives of people confronting devastating diseases of impaired muscle function.
SOUTH SAN FRANCISCO, Calif. , April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with spinal muscular atrophy (SMA) will be presented by John Day , M.D., Ph.D., Professor of Neurology and...
READ MORE ›als
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart Failure
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
sma
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.